Literature DB >> 10051649

Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.

B Chackerian1, D R Lowy, J T Schiller.   

Abstract

The vertebrate immune system has evolved to respond vigorously to microbial infection but to ignore self-antigens. Evidence has emerged that B cell responses to viruses are initiated by immune recognition of ordered arrays of antigen on the viral surface. To test whether autoantibodies against a self-antigen can be induced by placing it in a context that mimics the ordered surface of a viral particle, a peptide representing an extracellular loop of the mouse chemokine receptor CCR5 was incorporated into an immunodominant site of the bovine papillomavirus virus L1 coat protein, which self-assembles into virus-like particles. Mice inoculated with chimeric L1-CCR5 particles generated autoantibodies that bound to native mouse CCR5, inhibited binding of its ligand RANTES, and blocked HIV-1 infection of an indicator cell line expressing a human-mouse CCR5 chimera. These results suggest a general method for inducing autoantibodies against self-antigens, with diverse potential basic research and clinical applications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10051649      PMCID: PMC26791          DOI: 10.1073/pnas.96.5.2373

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Polymorphism in the assembly of polyomavirus capsid protein VP1.

Authors:  D M Salunke; D L Caspar; R L Garcea
Journal:  Biophys J       Date:  1989-11       Impact factor: 4.033

2.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

3.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

4.  The influence of antigen organization on B cell responsiveness.

Authors:  M F Bachmann; U H Rohrer; T M Kündig; K Bürki; H Hengartner; R M Zinkernagel
Journal:  Science       Date:  1993-11-26       Impact factor: 47.728

Review 5.  Molecular mimicry between non-self, modified self and self in autoimmunity.

Authors:  A E Karlsen; T Dyrberg
Journal:  Semin Immunol       Date:  1998-02       Impact factor: 11.130

Review 6.  Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease.

Authors:  R N Maini; M J Elliott; F M Brennan; R O Williams; C Q Chu; E Paleolog; P J Charles; P C Taylor; M Feldmann
Journal:  Immunol Rev       Date:  1995-04       Impact factor: 12.988

7.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

8.  V(D)J recombinase induction in splenic B lymphocytes is inhibited by antigen-receptor signalling.

Authors:  M Hertz; V Kouskoff; T Nakamura; D Nemazee
Journal:  Nature       Date:  1998-07-16       Impact factor: 49.962

9.  Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.

Authors:  R B Roden; E M Weissinger; D W Henderson; F Booy; R Kirnbauer; J F Mushinski; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

10.  A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.

Authors:  R Kirnbauer; N L Hubbert; C M Wheeler; T M Becker; D R Lowy; J T Schiller
Journal:  J Natl Cancer Inst       Date:  1994-04-06       Impact factor: 13.506

View more
  47 in total

1.  Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7.

Authors:  Jerri do Carmo Caldeira; Alexander Medford; Rhonda C Kines; Christopher A Lino; John T Schiller; Bryce Chackerian; David S Peabody
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

Review 2.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

3.  SplitCore Technology Allows Efficient Production of Virus-Like Particles Presenting a Receptor-Contacting Epitope of Human IgE.

Authors:  A Zh Baltabekova; Zh S Shagyrova; A S Kamzina; M Voykov; Ye Zhiyenbay; E M Ramanculov; A V Shustov
Journal:  Mol Biotechnol       Date:  2015-08       Impact factor: 2.695

4.  Combinatorial approach to hepadnavirus-like particle vaccine design.

Authors:  Jean-Noel Billaud; Darrell Peterson; Margaret Barr; Antony Chen; Matti Sallberg; Fermin Garduno; Phillip Goldstein; Wendy McDowell; Janice Hughes; Joyce Jones; David Milich
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.

Authors:  Zoe Hunter; Hugh D Smyth; Paul Durfee; Bryce Chackerian
Journal:  Vaccine       Date:  2009-10-20       Impact factor: 3.641

Review 6.  The Density Code for the Development of a Vaccine?

Authors:  Wei Cheng
Journal:  J Pharm Sci       Date:  2016-09-17       Impact factor: 3.534

7.  Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies.

Authors:  Yougang Zhai; Zhenyu Zhong; Mohammadreza Zariffard; Gregory T Spear; Liang Qiao
Journal:  Vaccine       Date:  2013-09-19       Impact factor: 3.641

8.  Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.

Authors:  Hongtao Zhang; Yujun Huang; Raja Fayad; Gregory T Spear; Liang Qiao
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

9.  Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88.

Authors:  Rongcun Yang; Francisco Martinez Murillo; Hengmi Cui; Richard Blosser; Satoshi Uematsu; Kiyoshi Takeda; Shizuo Akira; Raphael P Viscidi; Richard B S Roden
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres.

Authors:  Yoshihiko Murata; Paula M Lightfoote; Robert C Rose; Edward E Walsh
Journal:  Virol J       Date:  2009-06-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.